https://scholars.lib.ntu.edu.tw/handle/123456789/526477
Title: | Acute lymphoblastic leukemia occurring as a second malignant neoplasm in a child | Authors: | Liou M.-C. KAI-HSIN LIN MENG-YAO LU DONG-TSAMN LIN |
Keywords: | Acute lymphoblastic leukemia; Second malignant neoplasm | Issue Date: | 2002 | Journal Volume: | 101 | Journal Issue: | 7 | Start page/Pages: | 502-504 | Source: | Journal of the Formosan Medical Association | Abstract: | The effective treatment of childhood malignancies has increased the importance of early detection and treatment of second malignant neoplasms. Anticancer drugs may also be leukemogenic agents, by the same mechanisms that kill cancer cells. We report the case of a 10-year-old boy who had received radiotherapy and chemotherapy for the treatment of Ewing's sarcoma and developed acute lymphoblastic leukemia 22 months after the diagnosis of primary malignancy. Although chemotherapy is well known to potentiate the development of second acute nonlymphocytic leukemia, the pathogenic factors leading to second acute lymphoblastic leukemia remain obscure. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036657399&partnerID=40&md5=9405be4ec192dd256014d0995567e503 https://scholars.lib.ntu.edu.tw/handle/123456789/526477 |
ISSN: | 0929-6646 | SDG/Keyword: | antineoplastic agent; asparaginase; CD15 antigen; CD19 antigen; CD2 antigen; CD20 antigen; CD33 antigen; CD34 antigen; CD7 antigen; common acute lymphoblastic leukemia antigen; cyclophosphamide; cytarabine; dactinomycin; epirubicin; etoposide; HLA DR antigen; microsomal aminopeptidase; prednisolone; vincristine; acute lymphoblastic leukemia; article; cancer chemotherapy; cancer diagnosis; case report; childhood cancer; early diagnosis; Ewing sarcoma; human; karyotyping; leukemogenesis; male; pathogenesis; school child; second cancer; Bone Neoplasms; Child; Humans; Leukemia, Lymphocytic, Acute, L1; Male; Neoplasms, Second Primary; Sarcoma, Ewing's |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.